has found its second big ally from Big Pharma. The Carlsbad, Calif.-based company has forged what it calls its most lucrative partnership yet to discover, develop, and someday co-market microRNA drugs with Paris-based pharma giant sanofi-aventis
Regulus, formed in 2008 by Cambridge, Mass,-based Alnylam Pharmaceuticals
“This new alliance is indicative of the interest at pharmaceutical companies in new approaches for innovative medicines that have the potential to transform disease,” said Alnylam CEO John Maraganore, in a conference call this morning.
“We believe the future of Regulus is very bright,” said Isis CEO Stanley Crooke.
MicroRNA was only discovered in humans about a decade ago, but has emerged as one of the hottest concepts in biology. The idea behind Regulus and other microRNA-based efforts is to create drugs that can inhibit these specific stretches of RNA, which regulate how entire networks of proteins are expressed. By hitting switches that control protein networks, scientists hope to have success against complex diseases like diabetes, cancer, and inflammation that involve a symphony of multiple genes and proteins. Hitting these networks may have more power against these complex conditions than more traditional approaches that tend to rely on specifically inhibiting a single gene or protein, scientists say.
Exciting as it has all been for scientists, Regulus hasn’t yet brought any drug candidates into clinical trials. Regulus has said it hopes to start its first clinical trial in the second half of 2011. Regulus is racing against a number of competitors have also sprouted up to take advantage of the concept, including Denmark-based Santaris Pharma, Seattle-based Mirina, Boulder, Colo.-based Miragen Therapeutics, and Austin, Texas-based Mirna Therapeutics.
But at this point, Regulus appears to have secured the broadest support from Big Pharma partners. GlaxoSmithKline has actually formed two partnerships with Regulus, the second of which came back in February. The second deal calls for the companies to work together on a microRNA-blocking drug for hepatitis C, while the original deal called for Regulus to work on four inflammatory disease candidates.
The new deal with Sanofi will originally focus on four different targets for fibrosis, including Regulus’ lead program against microRNA-21. Sanofi is also getting an option to expand its use of the technology, which could generate another $50 million to Regulus if it’s exercised. Regulus stands to collect royalties on sales if any of the drug candidates become products, while Sanofi is responsible for 100 percent of the development and commercialization costs of the drugs, Regulus said in a statement.
Regulus has secured about $60 million in cash through its various partnerships and financings, which is enough to operate its business for several years, Regulus CEO Kleanthis Xanthopoulos said on the conference call.
Both Isis and Alnylam will receive $1.8 million payments from Regulus, or about a 7.5 percent cut of Regulus’ $25 million upfront payment. The parent companies, in a separate statement, said they are entitled to a similar percentage on future milestone payments that Regulus could earn from the Sanofi deal.
More from Xconomy.com:
- Illume's iZUP Mobile App Padlocks Cell Phones to Eliminate the Temptation to Talk or Text While Driving
- Glaxo Stops Study of Sirtris "Red Wine" Drug in Cancer Patients
- C-Crete Wins MIT $100K for Making Cleaner Concrete
Luke Timmerman is the National Biotechnology Editor for Xconomy, and the Editor of Xconomy Seattle. You can e-mail him at email@example.com, or call 206-624-2374.
More from The Motley Fool
3 Stocks That Could Put Amazon's Returns to Shame
These three tickers could be better bets than Amazon for new investors right now.
Will This iPhone Supplier’s Terrific Run Continue in 2018?
Lumentum's growing momentum in 3D sensing could help it overcome the weakness in the telecom segment.
3 Companies Best Positioned to Compete Against Amazon
There's more than one way to beat Amazon at its own game.